799 related articles for article (PubMed ID: 9725210)
1. Tumor-infiltrating lymphocytes exhibiting high ex vivo cytolytic activity fail to prevent murine melanoma tumor growth in vivo.
Prévost-Blondel A; Zimmermann C; Stemmer C; Kulmburg P; Rosenthal FM; Pircher H
J Immunol; 1998 Sep; 161(5):2187-94. PubMed ID: 9725210
[TBL] [Abstract][Full Text] [Related]
2. Differential requirement of perforin and IFN-gamma in CD8 T cell-mediated immune responses against B16.F10 melanoma cells expressing a viral antigen.
Prévost-Blondel A; Neuenhahn M; Rawiel M; Pircher H
Eur J Immunol; 2000 Sep; 30(9):2507-15. PubMed ID: 11009083
[TBL] [Abstract][Full Text] [Related]
3. Active antiviral T-lymphocyte response can be redirected against tumor cells by antitumor antibody x MHC/viral peptide conjugates.
Cesson V; Stirnemann K; Robert B; Luescher I; Filleron T; Corradin G; Mach JP; Donda A
Clin Cancer Res; 2006 Dec; 12(24):7422-30. PubMed ID: 17189415
[TBL] [Abstract][Full Text] [Related]
4. Biology of cloned cytotoxic T lymphocytes specific for lymphocytic choriomeningitis virus. VI. Migration and activity in vivo in acute and persistent infection.
Byrne JA; Oldstone MB
J Immunol; 1986 Jan; 136(2):698-704. PubMed ID: 2416821
[TBL] [Abstract][Full Text] [Related]
5. Vaccination with an adenoviral vector encoding the tumor antigen directly linked to invariant chain induces potent CD4(+) T-cell-independent CD8(+) T-cell-mediated tumor control.
Sorensen MR; Holst PJ; Pircher H; Christensen JP; Thomsen AR
Eur J Immunol; 2009 Oct; 39(10):2725-36. PubMed ID: 19637230
[TBL] [Abstract][Full Text] [Related]
6. In vivo treatment with a MHC class I-restricted blocking peptide can prevent virus-induced autoimmune diabetes.
von Herrath MG; Coon B; Lewicki H; Mazarguil H; Gairin JE; Oldstone MB
J Immunol; 1998 Nov; 161(9):5087-96. PubMed ID: 9794447
[TBL] [Abstract][Full Text] [Related]
7. Lysis of infected cells in vivo by antiviral cytolytic T cells demonstrated by release of cell internal viral proteins.
Kyburz D; Speiser DE; Battegay M; Hengartner H; Zinkernagel RM
Eur J Immunol; 1993 Jul; 23(7):1540-5. PubMed ID: 8325330
[TBL] [Abstract][Full Text] [Related]
8. The signal sequence of lymphocytic choriomeningitis virus contains an immunodominant cytotoxic T cell epitope that is restricted by both H-2D(b) and H-2K(b) molecules.
Hudrisier D; Oldstone MB; Gairin JE
Virology; 1997 Jul; 234(1):62-73. PubMed ID: 9234947
[TBL] [Abstract][Full Text] [Related]
9. T cell immunity after a viral infection versus T cell tolerance induced by soluble viral peptides.
Kyburz D; Aichele P; Speiser DE; Hengartner H; Zinkernagel RM; Pircher H
Eur J Immunol; 1993 Aug; 23(8):1956-62. PubMed ID: 8344359
[TBL] [Abstract][Full Text] [Related]
10. Protective immunity from naive CD8+ T cells activated in vitro with MHC class I binding immunogenic peptides and IL-2 in the absence of specialized APCs.
Hauser C; Zipprich F; Leblond I; Wirth S; Hügin AW
J Immunol; 1999 Jul; 163(1):330-6. PubMed ID: 10384132
[TBL] [Abstract][Full Text] [Related]
11. Decreased tumor surveillance after adoptive T-cell therapy.
Matter M; Pavelic V; Pinschewer DD; Mumprecht S; Eschli B; Giroglou T; von Laer D; Ochsenbein AF
Cancer Res; 2007 Aug; 67(15):7467-76. PubMed ID: 17671217
[TBL] [Abstract][Full Text] [Related]
12. Kinetics of the response of naive and memory CD8 T cells to antigen: similarities and differences.
Zimmermann C; Prévost-Blondel A; Blaser C; Pircher H
Eur J Immunol; 1999 Jan; 29(1):284-90. PubMed ID: 9933110
[TBL] [Abstract][Full Text] [Related]
13. Immunotherapy with dendritic cells and tumor major histocompatibility complex class I-derived peptides requires a high density of antigen on tumor cells.
Rawson P; Hermans IF; Huck SP; Roberts JM; Pircher H; Ronchese F
Cancer Res; 2000 Aug; 60(16):4493-8. PubMed ID: 10969797
[TBL] [Abstract][Full Text] [Related]
14. Lack of effector cell function and altered tetramer binding of tumor-infiltrating lymphocytes.
Blohm U; Roth E; Brommer K; Dumrese T; Rosenthal FM; Pircher H
J Immunol; 2002 Nov; 169(10):5522-30. PubMed ID: 12421928
[TBL] [Abstract][Full Text] [Related]
15. Antigen expressed on tumor cells fails to elicit an immune response, even in the presence of increased numbers of tumor-specific cytotoxic T lymphocyte precursors.
Hermans IF; Daish A; Yang J; Ritchie DS; Ronchese F
Cancer Res; 1998 Sep; 58(17):3909-17. PubMed ID: 9731502
[TBL] [Abstract][Full Text] [Related]
16. In vivo state of antiviral CTL precursors. Characterization of a cycling cell population containing CTL precursors in immune mice.
Razvi ES; Welsh RM; McFarland HI
J Immunol; 1995 Jan; 154(2):620-32. PubMed ID: 7529281
[TBL] [Abstract][Full Text] [Related]
17. Involvement of both T cell receptor V alpha and V beta variable region domains and alpha chain junctional region in viral antigen recognition.
Brändle D; Bürki K; Wallace VA; Rohrer UH; Mak TW; Malissen B; Hengartner H; Pircher H
Eur J Immunol; 1991 Sep; 21(9):2195-202. PubMed ID: 1716213
[TBL] [Abstract][Full Text] [Related]
18. Immunosuppressive activity of cloned natural killer (NK1.1+) T cells established from murine tumor-infiltrating lymphocytes.
Tamada K; Harada M; Abe K; Li T; Tada H; Onoe Y; Nomoto K
J Immunol; 1997 May; 158(10):4846-54. PubMed ID: 9144500
[TBL] [Abstract][Full Text] [Related]
19. Virus-specific cytotoxic T cell-mediated lysis of lymphocytes in vitro and in vivo.
Kyburz D; Speiser DE; Aebischer T; Hengartner H; Zinkernagel RM
J Immunol; 1993 Jun; 150(11):5051-8. PubMed ID: 7684417
[TBL] [Abstract][Full Text] [Related]
20. Homeostatic regulation of CD8+ T cells after antigen challenge in the absence of Fas (CD95).
Zimmermann C; Rawiel M; Blaser C; Kaufmann M; Pircher H
Eur J Immunol; 1996 Dec; 26(12):2903-10. PubMed ID: 8977284
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
